The company closed its plan on March 26, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
180,900 KRW | +0.72% | -2.85% | -10.22% |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.22% | 27.17B | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B | |
-9.26% | 11.19B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.